OBJECTIVE: To provide an updated state of the art about the role of positron emission tomography/computed tomography (PET/CT) with 11C-Choline and 18F-fluorocholine in the localized and locally advanced Prostate Cancer (PCa) in the staging and restaging setting. METHODS: We performed a non-systematic review of the literature based on a free-text search in the National Library of Medicine Database (MEDLINE) to select English-language published papers evaluating PET and PET/CT imaging with radiolabelled choline in initial diagnosis and in post-treatment phase in PCa patients. RESULTS: PET and PET/CT with 11C-choline and 18F-fluorocholine have been largely investigated as non-invasive diagnostic tools in PCa. Actually, the relatively high rate of false negative findings due to the small dimension of neoplastic lesions and the available spatial resolution of PET tracers limits the routine use of choline PET and PET/CT in staging setting; moreover, it cannot reliably replace the lymph node (LN) dissection for detecting LN involvement. On restaging setting, Choline PET/CT showed a higher accuracy than conventional imaging modalities, especially in the detection of LN and systemic metastases, while it is less accurate than magnetic resonance imaging in the detection of local relapse. CONCLUSION: In the Prostate Specific Antigen (PSA) era with a large number of localized disease, the diagnostic performance of choline PET and PET/CT lack of reliability in initial diagnosis of PCa. The major clinical role of choline PET/CT is the re-staging of patients with a biochemical relapse after radical treatment; the promising performance of choline PET/CT scan in patients with low levels of PSA could also lead the clinicians for to perform PET-guided adjuvant curative therapies or palliative treatments in patients already treated radically for PCa.
OBJECTIVE: To provide an updated state of the art about the role of positron emission tomography/computed tomography (PET/CT) with 11C-Choline and 18F-fluorocholine in the localized and locally advanced Prostate Cancer (PCa) in the staging and restaging setting. METHODS: We performed a non-systematic review of the literature based on a free-text search in the National Library of Medicine Database (MEDLINE) to select English-language published papers evaluating PET and PET/CT imaging with radiolabelled choline in initial diagnosis and in post-treatment phase in PCa patients. RESULTS: PET and PET/CT with 11C-choline and 18F-fluorocholine have been largely investigated as non-invasive diagnostic tools in PCa. Actually, the relatively high rate of false negative findings due to the small dimension of neoplastic lesions and the available spatial resolution of PET tracers limits the routine use of choline PET and PET/CT in staging setting; moreover, it cannot reliably replace the lymph node (LN) dissection for detecting LN involvement. On restaging setting, Choline PET/CT showed a higher accuracy than conventional imaging modalities, especially in the detection of LN and systemic metastases, while it is less accurate than magnetic resonance imaging in the detection of local relapse. CONCLUSION: In the Prostate Specific Antigen (PSA) era with a large number of localized disease, the diagnostic performance of choline PET and PET/CT lack of reliability in initial diagnosis of PCa. The major clinical role of choline PET/CT is the re-staging of patients with a biochemical relapse after radical treatment; the promising performance of choline PET/CT scan in patients with low levels of PSA could also lead the clinicians for to perform PET-guided adjuvant curative therapies or palliative treatments in patients already treated radically for PCa.
Authors: Mohammed N Tantawy; H Charles Manning; Todd E Peterson; Daniel C Colvin; John C Gore; Wenfu Lu; Zhenbang Chen; C Chad Quarles Journal: Mol Imaging Biol Date: 2018-04 Impact factor: 3.488
Authors: Angelo Porreca; Federico Mineo Bianchi; Antonio Salvaggio; Daniele D'Agostino; Alessandro Del Rosso; Daniele Romagnoli; Paolo Corsi; Michele Colicchia; Umberto Barbaresi; Lorenzo Bianchi; Marco Giampaoli; Riccardo Schiavina; Katie Palmer; Francesco Del Giudice; Martina Maggi; Matteo Ferro; Alessandro Sciarra; Ettore De Berardinis; Gian Maria Busetto Journal: World J Urol Date: 2020-07-03 Impact factor: 4.226
Authors: Angelo Porreca; Michele Colicchia; Daniele D'Agostino; Michele Amenta; Alfio Corsaro; Stefano Zaramella; Luisa Zegna; Fabrizio Gallo; Maurizio Schenone; Giorgio Bozzini; Alberto Calori; Antonio L Pastore; Yazan Al Salhi; Carmine Sciorio; Lorenzo Spirito; Virginia Varca; Carlo Marenghi; Francesco Greco; Vincenzo M Altieri; Paolo Verze; Ciro Barba; Alessandro Antonelli; Maria A Cerruto; Roberto Falabella; Silvana Di Bello; Costantino Leonardo; Antonio Tufano; Alessandro Volpe; Paolo Umari; Paolo Parma; Mattia Nidini; Giovannalberto Pini; Marco Borghesi; Carlo Terrone; Giovanni E Cacciamani; Maria C Sighinolfi; Gian Maria Busetto; Alexandra M Wennberg; Marinella Finocchiaro; Mario Falsaperla; Marco Oderda; Carlo Ceruti; Bernardo Rocco; Riccardo Schiavina; Lorenzo Bianchi; Andrea Mari; Fabrizio Di Maida; Orietta Dalpiaz; Antonio Celia; Marco Pirozzi; Pierluigi Bove; Valerio Iacovelli; Angelo Cafarelli; Luca Cindolo; Giovanni Ferrari; Lorenzo Gatti; Giacomo Pirola; Filippo Annino; Luigi Pucci; Daniele Romagnoli; Walter Artibani; Andrea Minervini Journal: Urol Int Date: 2020-05-20 Impact factor: 2.089
Authors: Angelo Porreca; Francesco Del Giudice; Marco Giampaoli; Daniele D'Agostino; Daniele Romagnoli; Paolo Corsi; Alessandro Del Rosso; Martina Maggi; Benjamin I Chung; Matteo Ferro; Ottavio de Cobelli; Giuseppe Lucarelli; Riccardo Schiavina; Ettore De Berardinis; Alessandro Sciarra; Gian Maria Busetto Journal: Medicine (Baltimore) Date: 2020-09-11 Impact factor: 1.817